42 • ODT odtmag.com July/August 2017
In addition to a bevy of platforms acquired through pur- chase, Zimmer Biomet maintains a comprehensive port- folio of orthopedic products by releasing a number of new
offerings throughout the year. 2016 was no different, as the
orthopedic giant was granted U.S. Food and Drug Administration (FDA) clearance for and launched a sizeable lot of new
technologies, spending $365 million on research and development activities. Although the company introduced 50 new
products last year, the most noteworthy are listed here.
Adding to the multinational’s extremities portfolio, February brought FDA 510(k) clearance to the Unite3D Bridge
Fixation System. An alternative to traditional surgical plates,
screws, and staples, the 3D-printed
technology provides stability in foot
and ankle joint fusion surgery through
an osteoconductive matrix for biological incorporation.
Three new hip portfolio products
were launched in March. The Echo Bi-Metric Microplasty Stem, a metaphyseal
loading, fit-and-fill femoral prosthesis
implanted through a broach-only technique, is 30 percent shorter than the
full-length stem, conserving natural
bone. The G7 Dual Mobility Construct
provides dislocation resistance without the need to constrain the femoral
head and expands the company’s shell,
fixation, and bearing options. The Arcos
One-Piece Femoral Revision System
features three fully porous, titanium
stem options with a range of sizes to address small femora.
Two implant technologies to support
the Persona Knee System and Vanguard
360 Revision System were also released
in March. Combining ultracongruent
designs with personalized femoral com-
ponents, the Persona Medial Congruent
Bearing recreates more natural knee mo-
tion by maximizing knee joint stability
throughout the range of motion. Osseo Ti
Tibial Sleeves address a range of cavitary
defects experienced in knee revision pro-
cedures with porous metal technology,
designed to distribute the load through
biologic fixation from the tibial plateau and stem to loads closer
to the joint. March also saw FDA 510(k) clearance for compat-
ibility of the Nexel Total Elbow System with the company’s
Comprehensive Segmental Revision System, streamlining
June saw a bunch of enhancements to the OSS Orthopedic
Salvage set of joint reconstruction prostheses. These include
modern implant designs for the distal femur and diaphysis,
small diameter Splined Stems, and new implant components
created with porous metal.
In July, the company unveiled Signature Solutions, a suite of
clinical services and technologies to help hospitals and medical practices transition into Comprehensive Care for Joint Replacement (CJR)-mandated value-based outcomes. Included
in the suite are interactive patient engagement tools to facilitate communication and patient adherence, a data mining
and analysis platform, and consulting
services with digital health software and
In September, the first-of-its-kind
Vanguard Individualized Design (ID)
knee replacement stepped into the market. It’s the first total knee construct to
permit a personalized fit while simplifying soft tissue preservation and balance.
Vanguard ID incorporates two polyethylene bearings with different articulations on the medial and lateral sides.
Due to Vanguard ID’s flexible design,
surgeons can use it to mix and match
bearings with different thickness and
geometry to personalize their approach
and preserve natural tissue.
November brought the launch of
the Comprehensive Vault Reconstruction System (VRS), the first commercially available patient-matched
Glenoid implant. It specifically treats
patients with a severely deficient rota-
tor cuff and considerable bone loss that
precludes using a standard baseplate.
VRS employs CT imaging and 3D re-
construction techniques for surgeons to
personalize each patient’s implant.
December saw an addition to the
biologics portfolio with the PrimaGen
Advanced Allograft. PrimaGen is an
autograft substitute containing a com-
bination of demineralized cortical bone
fibers with verified osteoinductivity and
cancellous bone. It is indicated for use as an allogeneic bone
graft substitute with viable donor cells intended for homolo-
gous use in repairing, replacing, reconstructing, or supple-
menting the recipient’s tissue in musculoskeletal defects.
Comprehensive VRS is the ;rst commercially
available patient-matched Glenoid implant.
Image courtesy of Zimmer Biomet.
VANGUARD ID is the ;rst total knee
construct to permit a personalized ;t while
simplifying soft tissue preservation and
balance. Image courtesy of Zimmer Biomet.